The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China.

Tirzepatide 與每週一次 Semaglutide 作為加用 metformin 治療中國第二型糖尿病患者之成本效用與預算影響分析